Professor Heather Payne, MBBS, FRCP, FRCR on Real-World Data on Apalutamide in nmCRPC
Emily Levitch
Expert Analysis
Presented at ESMO Virtual Congress 2020, a recent study compared results on apalutamide administered in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) between real-world data from an international named patient program (NPP) and the phase 3 SPARTAN clinical trial and found that the results were similar. In an interview w...
Frontline Pembrolizumab for PD-L1–Positive Gastric Cancer: Kohei Shitara, MD
Sarah Williams, MAT
Expert Analysis
Gastric or gastroesophageal junction (G/GEJ) cancer constitutes the third leading cause of cancer death worldwide, and more therapeutic options are needed. In results from the phase 3 KEYNOTE-062 study, published last week in JAMA Oncology, Kohei Shitara, MD, and colleagues reported that in patients with previously untreated G/GEJ cancer with a pro...
Neoadjuvant Nivolumab/Ipilimumab for Oral Cavity SCC: Jonathan Schoenfeld, MD, MPH
Keira Smith
Expert Analysis
Due to intensive treatments, severe side effects, and a high rate of recurrence, oral cavity squamous cell carcinoma (SCC) is a challenging disease associated with poor outcomes. According to a recent study, neoadjuvant nivolumab alone or in combination with ipilimumab may be a safe and effective treatment for patients with oral cavity SCC undergoi...
How Cancer Type Affects COVID-19 Outcomes: Lennard Lee, DPhil, MRCP, BMBCh
Keira Smith
Expert Analysis
While patients with cancer are at an increased risk of experiencing poor outcomes from COVID-19, there is significant variability in COVID-19 risk and mortality among patients with different tumor types and demographics such as age and sex, with those with hematologic malignancies facing the highest risk. In this interview with i3 Health, Lennard L...
Vivek Subbiah, MD, on Dabrafenib/Trametinib Efficacy in Biliary Tract Cancer
Emily Levitch
Expert Analysis
According to a recent study, led by Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, dabrafenib in combination with trametinib is an effective treatment option for patients with BRAFV600E -mutated biliary tract cancer (BTC). In an interview with i3 Health, Dr. Subbiah shares insights on the significance of these study result...
Geriatric and Surgical Comanagement for Older Patients With Cancer: Armin Shahrokni, MD, MPH
Keira Smith
Expert Analysis
Patients aged 75 years and older face an increased risk of mortality and postoperative events when undergoing surgical treatment for cancer. In a study recently published in JAMA Network Open, a research team led by first author Armin Shahrokni, MD, MPH, found that patients whose care was managed by both the surgical and geriatric teams experienced...
Hans C. Lee, MD: FDA Approval of Belantamab Mafodotin-blmf for R/R Multiple Myeloma
Emily Levitch
Expert Analysis
For patients with relapsed or refractory (R/R) multiple myeloma (MM), a new treatment has just been recently FDA approved: belantamab mafodotin-blmf (BLENREP®, GlaxoSmithKline). In an interview with i3 Health, Hans C. Lee, MD, of The University of Texas MD Anderson Cancer Center, speaks about the significance of this approval and what the future ma...
Tafasitamab/Lenalidomide for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Gilles Salles, MD, PhD
Sarah Williams, MAT
Expert Analysis
Recently, the FDA granted accelerated approval to tafasitamab-cxix (Monjuvi®, MorphoSys US Inc.) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. In this interview with i3 Health, Gilles Salles, MD, PhD, principal investigator o...
Atezolizumab Triplet Therapy for BRAF V600-Mutant Melanoma: Paolo A. Ascierto, MD
Sarah Williams, MAT
Expert Analysis
Recently, the FDA approved a new indication for atezolizumab (Tecentriq®, Genentech) in combination with vemurafenib (Zelboraf®, Genentech and Daiichi-Sankyo) and cobimetinib (Cotellic®, Genentech) for the treatment of BRAF V600-mutant advanced melanoma. In this interview with i3 Health, Paolo A. Ascierto, MD, principal investigator of the IMspire1...
​Connecting With Patients With Cancer in Spite of COVID-19: Kiri A. Cook, MD
Sarah Williams, MAT
Expert Analysis
The stress of having cancer and the physical and financial toll of treatment can be difficult for patients, even under normal circumstances. During the COVID-19 pandemic, patients face additional stressors, including not only the fear of mortality from COVID-19 but also the emotional impact of isolation. This sense of isolation can be pre...
IVC Filter Efficacy in Patients With Cancer and Deep Vein Thrombosis: Rahul A. Sheth, MD
Sarah Williams, MAT
Expert Analysis
Patients with cancer are at substantially increased risk for deep vein thrombosis (DVT) and resulting pulmonary embolism. Together, these two forms of venous thromboembolism constitute the second leading cause of death for patients with known malignancies. The standard of care for DVT is anticoagulation, yet many patients with cancer and DVT are un...
Cancer Overscreening in Older Adults: Jennifer L. Moss, PhD
Keira Smith
Expert Analysis
According to a study recently published in JAMA Network Open, a high proportion of older adults with average cancer risk are overscreened for colorectal, cervical, and breast cancers after surpassing specified upper age limits recommended by the US Preventive Services Task Force (USPSTF). In this interview, Jennifer L. Moss, PhD, first author of th...
Oral Decitabine/Cedazuridine for MDS: Olatoyosi Odenike, MD
Keira Smith
Expert Analysis
In this interview, Olatoyosi Odenike, MD, speaks with i3 Health about the approval of oral decitabine/cedazuridine (Inqovi®, Astex Pharmaceuticals, Inc.) for adult patients with myelodysplastic syndromes (MDS). Dr. Odenike, Director of the Leukemia Program at the University of Chicago and an investigator of one of the clinical trials on which the a...
Breast Cancer Chemotherapy in Older Patients With Comorbidities: Nina Tamirisa, MD
Sarah Williams, MAT
Expert Analysis
Many older patients with breast cancer have significant comorbidities, increasing the challenges of treatment. These challenges are compounded by the fact that elderly patients with multiple comorbidities are frequently excluded from participating in clinical trials, resulting in a lack of treatment data for this population. Nina Tamirisa, MD, and ...
Lurbinectedin for Small-Cell Lung Cancer: Luis Paz-Ares, MD
Sarah Williams, MAT
Expert Analysis
Last month, the FDA granted accelerated approval to lurbinectedin (ZepzelcaTM, Pharma Mar, S.A.) for adults with metastatic small-cell lung cancer experiencing disease progression on or after platinum-based chemotherapy. In this interview, Luis Paz-Ares, MD, principal investigator of the phase 2 basket trial PM1183-B-005-14 (Study B-005; NCT0245497...
Murray Brunt, MBBS on 10-Year Results of FAST: 5-Fraction RT for Breast Cancer
Emily Levitch
Expert Analysis
Ten-year results from the FAST study show that there are no significant differences in normal tissue effects (NTE) rates after 28.5 Gy/5 fractions (fr) compared with 50 Gy/25 fr in patients with early breast cancer; however, NTE were higher with 30 Gy/5 fr, according to a study published in the Journal of Clinical Oncology. In an interview with i3 ...
John Leonard, MD: FDA Approval of Selinexor for DLBCL
Emily Levitch
Expert Analysis
Selinexor (Xpovio®, Karyopharm Therapeutics) was recently FDA approved to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This approval extends to patients with DLBCL that resulted from follicular lymphoma and those who had previously received at least two prior lines of systemic therapy. John Leonard, MD, the Richard T. Silver Dis...
Hypertensive Medications and Reduced Colorectal Cancer Risk: Wai K. Leung, MD
Keira Smith
Expert Analysis
In this interview, Wai K. Leung, MD, speaks with i3 Health about his research team's finding, recently published in Hypertension, that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with a decreased risk of colorectal cancer within three years of colonoscopy. Dr. Leung discusses the significan...
Avelumab for Urothelial Carcinoma: An Interview With Thomas Powles, MBBS, MRCP, MD
Emily Levitch
Expert Analysis
The FDA recently approved avelumab (Bavencio®, EMD Serono, Inc.) for patients with advanced urothelial carcinoma (UC). Thomas Powles, MBBS, MRCP, MD, discusses with i3 Health the implication of this approval and future steps for research and offers community oncologists advice on treating this patient population. What are the most challenging aspec...
The Changing Standards for FDA Oncology Approvals: Talal Hilal, MD
Sarah Williams, MAT
Expert Analysis
The FDA approval process is in place to ensure that drugs are safe and effective before they are made available to the public. But do the clinical trials that lead to approval truly ascertain whether a drug is efficacious? Fully two-thirds of anticancer drug clinical trials leading to FDA approvals between 2014 and 2019 had at least one import...

Copyright © 2022 Oncology Data Advisor. All rights reserved.